The most popular FierceBiotech stories of 2015

Why would Martin Shkreli hike an old drug price by 5,000%? Only a 'moron' would ask
Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old rare-disease drug, Thiola, and raising the price 2000%. Now that he's on to his next company, Turing Pharmaceuticals, he's done himself one better, by buying another old drug and boosting the price 5,000%. More

Why Axovant's $315M IPO bonanza should scare the hell out of you
Vivek Ramaswamy may not know anything about biotech and even less about treating Alzheimer's, but he just provided a master class on the current state of public investing and executing IPOs in the field. The bare bones of Ramaswamy's new biotech venture, Axovant, are much discussed these days. The former hedge fund manager grabbed an abandoned GlaxoSmithKline drug for Alzheimer's for $5 million. More

Shkreli's Turing Pharma banks $90M in a murky funding round
Turing Pharmaceuticals, led by an outspoken former hedge fund manager, raised $90 million from its own CEO and some unnamed benefactors, at the same time buying a treatment for infectious disease to flesh out its pipeline. The company, headquartered in New York and Switzerland, is the latest biotech play from Martin Shkreli, a stock picker turned biotech CEO whose first startup, Retrophin, forced him out last year. More

Suicide stunner prompts Amgen to dump brodalumab, denting AstraZeneca's rep
A month ago, Amgen and AstraZeneca were confidently rolling up data from three highly touted late-stage studies on the psoriasis drug brodalumab for a new drug application that was widely viewed as a shoo-in at the FDA. But late Friday evening, as the industry was heading out for a long Memorial Day weekend, Amgen abruptly said it was pulling out of the long-running collaboration on the high-profile IL-17 program after evaluating the likely commercial impact it would face in light of the suicidal thoughts some patients reported during the studies. More

Genocea's herpes vaccine hits the mark in Phase II
Genocea Biosciences' in-development vaccine for genital herpes met its goals in a Phase II trial, sending the biotech's shares soaring. The protein treatment, GEN-003, works by galvanizing the body's T and B cells to attack herpes, and, in a 310-patient trial, the vaccine significantly beat out placebo in tamping down viral activity. More

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.